mTOR inhibitors

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Protein complexes, Signal transduction, mTORC1, G proteins, MTOR, Tumor suppressor gene, Ras GTPase, Cancer, mTOR inhibitors

Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.

Key Points: 
  • Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.
  • The compound is designed to inhibit mTORC1 and thereby protect the natural tumor suppressor activity of 4EBP1, without the undesirable inhibition of mTORC2.
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.
  • RAS(ON) Inhibitors in development include RMC-6291 and RMC-6236, and a pipeline of research compounds targeting additional RAS variants.

Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Signal transduction, Biology, mTOR inhibitors, Oncology, MTOR, CBR96-doxorubicin immunoconjugate

Patients had a median of 3.5 lines of prior therapy and 6 of 8 patients were mTOR inhibitor-nave.

Key Points: 
  • Patients had a median of 3.5 lines of prior therapy and 6 of 8 patients were mTOR inhibitor-nave.
  • Five of 8 patients continued on treatment as of the data cutoff and 3 of 8 patients discontinued.
  • Of the 8 patients treated, 7 patients were evaluable for response analysis and 1 patient progressed before the first scan.
  • Dr. Neil Desai, founder and chief executive officer of Aadi, stated, "We are pleased to have provided FYARRO to patients through our expanded access program.

Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers

Retrieved on: 
Thursday, March 11, 2021
Lymphoma, Clinical medicine, Branches of biology, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma, Medicine, Antineoplastic drugs, Signal transduction, mTOR inhibitors, SeaGen

Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.

Key Points: 
  • Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
  • Pacylex is a pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta, Canada.
  • PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment.
  • Pacylex expects to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors.

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Signal transduction, Biology, Protein kinases, Oncology, PI3K/AKT/mTOR pathway, MTOR, Protein kinase B, Phosphoinositide 3-kinase, Diffusion Pharmaceuticals, Phosphoinositide 3-kinase inhibitor, mTOR inhibitors

Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.

Key Points: 
  • Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.
  • Our presentation will be available here , on the Investor Relations section of our website following the conference.
  • Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusions product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Biology, Signal transduction, Oncology, Cell signaling, MTOR, Phosphoinositide 3-kinase, Apoptosis, Protein kinase B, mTOR inhibitors, Phosphoinositide 3-kinase inhibitor

These data also show that the downregulation of these oncoproteins correlates with apoptosis (programmed cell death) and tumor regression in vivo.

Key Points: 
  • These data also show that the downregulation of these oncoproteins correlates with apoptosis (programmed cell death) and tumor regression in vivo.
  • Further, vertical inhibition of the PI3K-AKT-mTOR-eIF4F pathway through combination of zotatifin with other agents acting in the pathway provided a synergistic effect in RTK-driven tumors.
  • These data informed our selection strategy for monotherapy and combination clinical expansion cohorts anticipated to start in early 2021.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is in a dose-escalation Phase 1 trial, with expansion cohorts expected to open in H1 2021.

Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations

Retrieved on: 
Monday, August 3, 2020
Branches of biology, Health, Signal transduction, Biology, Drug discovery, mTOR inhibitors, Oncology, Cystic hygroma, Orphan drug, MTOR

and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).

Key Points: 
  • and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).
  • Lymphatic malformations are a family of rare, congenital neoplastic diseases caused by mutations in certain genes that regulate cell growth in the lymphatic system.
  • Cerecor is a leading biopharmaceutical company focused on in development and commercialization of treatments for rare pediatric and orphan diseases.
  • CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex Lymphatic Malformations.

eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease

Retrieved on: 
Monday, April 27, 2020
Cancer treatments, Medicine, Clinical medicine, Cancer, KRAS, Predictive marker, mTOR inhibitors

In a HER2+ breast cancer model, tumor regression was sustained long after cessation of therapy.

Key Points: 
  • In a HER2+ breast cancer model, tumor regression was sustained long after cessation of therapy.
  • Further evaluation of predictive markers of sensitivity or resistance showed that RTK tumor models with mTOR mediated activation of eIF4A are most sensitive to zotatifin.
  • This selection strategy will complement our selection of KRAS-mutant tumors based on zotatifins down-regulation of KRAS protein in preclinical studies.
  • A Phase 1/2 clinical trial of zotatifin in patients with KRAS- or RTK-mutant solid tumors is ongoing [NCT04092673].

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

Retrieved on: 
Friday, March 6, 2020
Branches of biology, Medicine, Signal transduction, Clinical medicine, Genodermatoses, Pachyonychia congenita, mTOR inhibitors, Sirolimus, MTOR, PC, PTX

VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.

Key Points: 
  • VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.
  • Palvella also intends to initiate an open-label extension program where patients will have the option to continue to receive study drug.
  • PTX-022 is supported by multiple issued method-of-use patents in the U.S. broadly covering the use of mTOR inhibitors in pachyonychia congenita.
  • Palvellas lead program, PTX-022 (QTORIN 3.9% rapamycin anhydrous gel), is in Phase 2/3 development for pachyonychia congenita, a rare, chronically debilitating and lifelong genetic disease.